Kyntra Bio SEC filings document the former FibroGen public-company record, including the completed 2026 name change and common-stock ticker transition from FGEN to KYNB. Material-event reports cover operating results, clinical and regulatory disclosures for FG-3246, FG-3180 and roxadustat, capital-structure matters, Nasdaq continued-listing compliance notices, and the completed sale of FibroGen International (Hong Kong) Ltd. and related pro forma financial information.
Proxy materials address shareholder voting matters, board and governance practices, executive compensation, equity awards and related corporate-control disclosures. The filing record also includes formal amendments to organizational documents and other 8-K disclosures tied to the company’s biopharmaceutical development focus and corporate transformation.
Kyntra Bio, Inc. reported an option grant to its Chief Financial Officer, David DeLucia. On 02/03/2026, he was awarded a stock option for 26,000 shares of common stock at an exercise price of $8.50 per share.
The option vests in equal amounts quarterly over four years starting on 02/03/2026. Following this grant, DeLucia beneficially owns 26,000 derivative securities directly through this option award.
FibroGen, Inc. has changed its corporate name to Kyntra Bio, Inc. following the filing of a Certificate of Amendment to its Amended and Restated Certificate of Incorporation with the State of Delaware on December 29, 2025. The name change becomes effective at 4:30 p.m. Eastern Time on January 7, 2026.
The board also approved a conforming amendment to the company’s Bylaws, effective at the same time, to update the Bylaws’ title to Kyntra Bio, Inc. In connection with the rebranding, the company’s common stock, previously trading under the symbol “FGEN” on The Nasdaq Global Select Market, will begin trading under the new symbol “KYNB” at the market open on January 8, 2026. The CUSIP number for the common stock remains unchanged.
FibroGen, Inc. (FGEN) reported insider buying by its Chief Executive Officer and Director in a Form 4 filing. On 11/13/2025, the reporting person purchased 1,000 shares of common stock at $9.18 per share. On 11/17/2025, an additional 2,700 shares were purchased at $9.0999 per share. After these transactions, the reporting person beneficially owned 24,939 shares of FibroGen common stock directly and 40 shares indirectly through a spouse. The filing was made by a single reporting person in the roles of both CEO and Director.
FibroGen, Inc. (FGEN) reported Q3 2025 results highlighted by the divestiture of its China operations to AstraZeneca for total consideration of $220.4 million. The company received $210.4 million at closing on August 29, 2025 and used approximately $80.9 million to repay its senior secured term loan facilities, interest, and related fees.
Results reflect discontinued operations for China: income from discontinued operations was $213.8 million in the quarter, including a $52.2 million gain on divestiture. From continuing operations, revenue was $1.1 million and loss was $13.1 million. Net income was $200.6 million, driven by the discontinued operations gain. Cash and cash equivalents were $118.0 million as of September 30, 2025, up from $50.5 million at year-end 2024.
The company effected a 1‑for‑25 reverse stock split on June 16, 2025. Shares outstanding were 4,045,445 as of October 31, 2025. Management now believes existing cash will fund planned operating requirements for at least 12 months following issuance. FibroGen initiated a Phase 2 study of FG‑3246 in mCRPC and aligned with the FDA on key elements of a planned Phase 3 for roxadustat in lower‑risk MDS.
FibroGen, Inc. furnished an 8-K to announce it issued a press release with financial results for the quarter ended September 30, 2025. The press release is provided as Exhibit 99.1.
The company states the information under Item 2.02, including Exhibit 99.1, is not deemed “filed” under the Exchange Act and will not be incorporated by reference into other SEC filings.
FibroGen, Inc. reported receipt of a $6.4 million payment from AstraZeneca. The amount reflects release of the first $6.0 million holdback under their February 20, 2025 share purchase agreement, plus $0.4 million from final net cash adjustments after closing.
This relates to FibroGen’s August 29, 2025 sale of its China operations to AstraZeneca for approximately $220 million, comprised of $85 million in enterprise value and about $135 million in net cash held in China. Of the total, $210 million was paid at closing, with an additional $10.0 million subject to holdbacks: the now-released $6.0 million cash-adjustment holdback and a separate $4.0 million indemnity holdback to be released, net of any claims paid or unresolved, nine months after closing.
David DeLucia, Chief Financial Officer of FibroGen, Inc. (FGEN), reported two dispositions of common stock that were withheld to satisfy tax obligations arising from the vesting of restricted stock units. The Form 4 lists a transaction on 06/06/2025 showing a disposition at a price of $7.8325 and a reported beneficial ownership of 4,594 shares following the transaction. A second reported disposition on 09/06/2025 shows a price of $12.10 and a reported beneficial ownership of 4,541 shares following that transaction. The filer states these shares were withheld by the issuer to cover taxes on RSU vesting. The filing notes a 1-for-25 reverse stock split effective June 16, 2025. The Form 4 is signed by an attorney-in-fact on behalf of the reporting person.
Thane Wettig, listed as CEO and Director of FibroGen, Inc. (FGEN), reported two stock disposals in 2025 and an indirect holding by his spouse. On 06/06/2025 he disposed of 21,487 shares at a reported price of $7.8325, and on 09/06/2025 he disposed of 21,239 shares at $12.10. The filing states these share amounts were withheld by the issuer to satisfy a tax obligation arising from the vesting of restricted stock units.
The form also notes an indirect beneficial ownership of 40 shares by his spouse. A 1-for-25 reverse stock split effective June 16, 2025 is disclosed and the reported share counts and prices reflect that split. The form is signed by an attorney-in-fact on behalf of the reporting person.
FibroGen, Inc. completed the sale of all issued and outstanding equity interests of its subsidiary FibroGen International (Hong Kong) Ltd. to AstraZeneca Treasury Limited on August 29, 2025 for approximately $220 million, closing a previously announced transaction under a Share Purchase Agreement dated February 20, 2025. The deal represents a disposition of assets associated with FibroGen’s China anemia business structure. The company also provided unaudited pro forma condensed consolidated financial information, including a balance sheet as of June 30, 2025 and statements of operations for the year ended December 31, 2024, in Exhibit 99.1 to help illustrate the financial impact of this divestiture.
FibroGen, Inc. reported that it has completed the sale of FibroGen International (Hong Kong) Ltd., including its FibroGen China operations, to AstraZeneca Treasury Limited for total consideration of approximately $220 million. This amount consists of $85 million in enterprise value and about $135 million in net cash held in China, with $6.0 million held back for final cash adjustments and $4.0 million held back for potential indemnity claims.
FibroGen and a subsidiary sold all equity interests in the Hong Kong entity and its China roxadustat assets to AstraZeneca, which has long partnered with FibroGen on roxadustat in greater China and South Korea. FibroGen keeps roxadustat rights in the United States, Canada, Mexico, and other territories not held by AstraZeneca or licensed to Astellas Pharma Inc. At closing, FibroGen repaid its term loan facility with investment funds managed by Morgan Stanley Tactical Value for approximately $81 million.